Literature DB >> 33404937

A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis.

Soudeh Ghafouri-Fard1, Kasra Honarmand1, Mohammad Taheri2.   

Abstract

Multiple sclerosis (MS) as a chronic inflammatory disorder of the central nervous system (CNS) is thought to be caused by the abnormal induction of immune responses. Chemokines as molecules that can engage leukocytes into the location of inflammation, actively participate in the pathogenesis of MS. Several members of this family of chemo attractants have been shown to be dysregulated in the peripheral blood, cerebrospinal fluid or CNS lesions of MS patients. Studies in animal models of MS particularly experimental autoimmune encephalomyelitis have indicated the critical roles of chemokines in the pathophysiology of MS. In the current review, we summarize the data regarding the role of CCL2, CCL3, CCL4, CCL11, CCL20, CXCL1, CXCL2, CXCL8, CXCL10, CXCL12 and CXCL13 in the pathogenesis of MS.

Entities:  

Keywords:  CC chemokine receptors; CXC chemokine receptors; Multiple sclerosis; chemokine

Year:  2021        PMID: 33404937     DOI: 10.1007/s11011-020-00648-6

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  160 in total

1.  Regional neural activation defines a gateway for autoreactive T cells to cross the blood-brain barrier.

Authors:  Yasunobu Arima; Masaya Harada; Daisuke Kamimura; Jin-Haeng Park; Fuminori Kawano; Fiona E Yull; Tadafumi Kawamoto; Yoichiro Iwakura; Ulrich A K Betz; Gabriel Márquez; Timothy S Blackwell; Yoshinobu Ohira; Toshio Hirano; Masaaki Murakami
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

2.  The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease.

Authors:  H Bartosik-Psujek; Z Stelmasiak
Journal:  Eur J Neurol       Date:  2005-01       Impact factor: 6.089

3.  Region-specific regulation of inflammation and pathogenesis in experimental autoimmune encephalomyelitis.

Authors:  Angela S Archambault; Julia Sim; Erin E McCandless; Robyn S Klein; John H Russell
Journal:  J Neuroimmunol       Date:  2006-10-09       Impact factor: 3.478

4.  Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Authors:  Markus Axelsson; Clas Malmeström; Martin Gunnarsson; Henrik Zetterberg; Peter Sundström; Jan Lycke; Anders Svenningsson
Journal:  Mult Scler       Date:  2013-05-23       Impact factor: 6.312

5.  The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.

Authors:  Markus Axelsson; Niklas Mattsson; Clas Malmeström; Henrik Zetterberg; Jan Lycke
Journal:  J Neuroimmunol       Date:  2013-09-18       Impact factor: 3.478

6.  Neuronal expression of the transcription factor serum response factor modulates myelination in a mouse multiple sclerosis model.

Authors:  Sofia Anastasiadou; Sophie Liebenehm; Daniela Sinske; Christopher Meyer zu Reckendorf; Barbara Moepps; Alfred Nordheim; Bernd Knöll
Journal:  Glia       Date:  2015-02-02       Impact factor: 7.452

7.  The SDF-1 3'a genetic variation of the chemokine SDF-1α (CXCL12) in parallel with its increased circulating levels is associated with susceptibility to MS: a study on Iranian multiple sclerosis patients.

Authors:  Hossein Azin; Reza Vazirinejad; Behzad Nasiri Ahmadabadi; Hossein Khorramdelazad; Ebrahim Rezazadeh Zarandi; Mohammad Kazemi Arababadi; Mojgan Noroozi Karimabad; Ali Shamsizadeh; Houshang Rafatpanah; Gholamhossein Hassanshahi
Journal:  J Mol Neurosci       Date:  2011-11-29       Impact factor: 3.444

8.  CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.

Authors:  Enrique Alvarez; Laura Piccio; Robert J Mikesell; Eric C Klawiter; Becky J Parks; Robert T Naismith; Anne H Cross
Journal:  Mult Scler       Date:  2013-01-15       Impact factor: 6.312

9.  Quantitative evaluation of CXCL8 and its receptors (CXCR1 and CXCR2) gene expression in Iranian patients with multiple sclerosis.

Authors:  Shohreh Almasi; Mohammad Reza Aliparasti; Mehdi Farhoudi; Zohreh Babaloo; Behzad Baradaran; Fatemeh Zamani; Homayoun Sadeghi-Bazargani; Somaiyeh Mostafaei; Elyar Sadeghi Hokmabadi
Journal:  Immunol Invest       Date:  2013-07-22       Impact factor: 3.657

10.  Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS.

Authors:  Alicia A Babcock; William A Kuziel; Serge Rivest; Trevor Owens
Journal:  J Neurosci       Date:  2003-08-27       Impact factor: 6.167

View more
  4 in total

1.  CCL4 induces inflammatory signalling and barrier disruption in the neurovascular endothelium.

Authors:  Carolina Estevao; Chantelle E Bowers; Ding Luo; Mosharraf Sarker; Alexandra Eva Hoeh; Karen Frudd; Patric Turowski; John Greenwood
Journal:  Brain Behav Immun Health       Date:  2021-10-22

2.  Microglia-derived CCL2 has a prime role in neocortex neuroinflammation.

Authors:  Mariella Errede; Tiziana Annese; Nicole Kerlero de Rosbo; Daniela Virgintino; Valentina Petrosino; Giovanna Longo; Francesco Girolamo; Ignazio de Trizio; Antonio d'Amati; Antonio Uccelli
Journal:  Fluids Barriers CNS       Date:  2022-08-30

3.  Identification of key genes and microRNAs for multiple sclerosis using bioinformatics analysis.

Authors:  Zhong-Bo Xu; Xin Feng; Wei-Na Zhu; Ming-Liang Qiu
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

Review 4.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.